59 reports

  • Chemotherapy Induced Neutropenia

The POLT-HCV-SVR trial, initiated in the second quarter of 2014, enrolled post-orthotopic liver transplant (POLT) recipients whose transplanted livers were damaged by recurrent HCV infection.

  • Chemotherapy
  • United States
  • World
  • Product Initiative
  • BeyondSpring Pharmaceuticals Inc.

Continued progression over time ultimately leads to liver transplant or liver failure.

  • Chemotherapy
  • United States
  • World
  • Product Initiative
  • Conatus Pharmaceuticals Inc.
  • Clinical Trial profile. 321 Trial Title
  • Clinical Trial profile. 142 Trial Title

Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Estimated Start Date Actual Start date Estimated Completion Date # of Subjects Planned # of Location(s) #

  • Chemotherapy
  • Clinical Trial
  • Hepatitis
  • Therapy
  • World

THE DRUG CANDIDATE IS IN PHASE II STAGE OF DEVELOPMENT FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, NONALCOHOLIC FATTY LIVER DISEASE, HCV RECURRENCE POST TRANSPLANT, RENAL IMPAIREMENT, AUTOIMMUNE HEPATITIS, PORTAL HYPERTENSION, ACUTE-ONCHRONIC LIVER FAILURE,

  • Chemotherapy
  • Digestive System Disorder
  • Immunotherapy
  • Therapy
  • Conatus Pharmaceuticals Inc.

It is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant and liver transplant.

  • Cancer
  • Chemotherapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Chemotherapy
  • Hospital
  • Lung Cancer
  • United States
  • Merck & Co., Inc.

THE DRUG CANDIDATE IS IN PHASE II STAGE OF DEVELOPMENT FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, NONALCOHOLIC FATTY LIVER DISEASE, HCV RECURRENCE POST TRANSPLANT, RENAL IMPAIRMENT, AUTOIMMUNE HEPATITIS, PORTAL HYPERTENSION, ACUTE-ONCHRONIC LIVER FAILURE,

  • Chemotherapy
  • Digestive System Disorder
  • World
  • Product Initiative
  • Conatus Pharmaceuticals Inc.

In May 2015, Zenyaku Kogyo Co. received an orphan designation for rituximab (##yaku) No. ## for the treatment of kidney transplantation and liver transplantation. ##-Jun-2019 Genentech announced that the U. S.

  • Chemotherapy
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

The POLT-HCV-SVR trial, initiated in the second quarter of 2014, enrolled post-orthotopic liver transplant (POLT) recipients whose transplanted livers were damaged by recurrent HCV infection.

  • Chemotherapy
  • Digestive System Disorder
  • United States
  • World
  • Product Initiative

THE DRUG CANDIDATE IS IN PHASE II STAGE OF DEVELOPMENT FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, NONALCOHOLIC FATTY LIVER DISEASE, HCV RECURRENCE POST TRANSPLANT, RENAL IMPAIRMENT, AUTOIMMUNE HEPATITIS, PORTAL HYPERTENSION, ACUTE-ONCHRONIC LIVER FAILURE,

  • Chemotherapy
  • China
  • United States
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Blood Disease
  • Chemotherapy
  • Clinical Trial
  • Leukemia
  • Novartis AG

The POLT-HCV-SVR trial, initiated in the second quarter of 2014, enrolled post-orthotopic liver transplant (POLT) recipients whose transplanted livers were damaged by recurrent HCV infection.

  • Chemotherapy
  • Digestive System Disorder
  • Therapy
  • United States
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

## ## ## ## Pfizer Inc Omnicare Pharma Gmbh Merck & Co Inc ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Humanigen Inc ## ## ## ## ## ## Eisai Co Ltd ## ## ## ## ## ## Celgene Corp ## ## ## ## ## ## Bio

  • Chemotherapy
  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative

The liver is one of the largest organs in the body.

  • Chemotherapy
  • China
  • Demand
  • Trade
  • Hainan Haiyao Company Limited

It is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant and liver transplant.

  • Cancer
  • Chemotherapy
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Cancer
  • Chemotherapy
  • North America
  • United States
  • Merck & Co., Inc.

The liver is one of the largest organs in the body.

  • Chemotherapy
  • China
  • Demand
  • Novartis AG
  • Sanofi-Synthelabo Inc.

The prominent features of this report are - ##.

  • Chemotherapy
  • Clinical Trial
  • Neurology
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Cancer
  • Chemotherapy
  • Clinical Trial
  • Therapy
  • GlaxoSmithKline plc

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## C.

  • Chemotherapy
  • Clinical Trial
  • Medical Biotechnology
  • World
  • Product Initiative

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Cancer
  • Chemotherapy
  • United States
  • Product Initiative
  • Eisai Co., Ltd.

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Cancer
  • Chemotherapy
  • Hospital
  • Therapy
  • Merck & Co., Inc.
  • 5. All the trials included are unique trials.

An Open Labelled Randomized Everolimus Vs Calcineurin Inhibitors Multicenter Trial (CERTICOEUR) A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients.

  • Chemotherapy
  • Lung Cancer
  • Monoclonal Antibody
  • World
  • Product Initiative

THE STUDY WILL TEST TWO DIFFERENT DOSES OF THE DRUG TO BE SAFER IN PEOPLE NEEDING A LIVER TRANSPLANT AND THE DOSE CHOSEN WILL BE USED IN FURTHER STUDIES TO TEST ART-## TO REDUCE THE CHANCES OF EARLY ALLOGRAFT DYSFUNCTION OCCURRING IN PATIENTS WHO HAVE A LIVER

  • Chemotherapy
  • Drug Development
  • United States
  • Company
  • Product Initiative

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Chemotherapy
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Takeda Pharmaceutical Company Ltd ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## Neopharm Ltd ## ## ## ## ## ## ## ## Mallinckrodt Plc ## ## ## ## ## ## ## ## Bellicum Pharmaceutic

  • Chemotherapy
  • Drug Development
  • Pharmaceutical
  • Transplantation
  • World

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Chemotherapy
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Chemotherapy
  • Hospital
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

THE STUDY WILL TEST TWO DIFFERENT DOSES OF THE DRUG TO BE SAFER IN PEOPLE NEEDING A LIVER TRANSPLANT AND THE DOSE CHOSEN WILL BE USED IN FURTHER STUDIES TO TEST ART-## TO REDUCE THE CHANCES OF EARLY ALLOGRAFT DYSFUNCTION OCCURRING IN PATIENTS WHO HAVE A LIVER

  • Chemotherapy
  • Neurological Disorder
  • Pharmaceutical
  • United States
  • Product Initiative

IT IS INDICATED FOR THE PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A KIDNEY TRANSPLANT AND LIVER TRANSPLANT.

  • Chemotherapy
  • Lung Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.